Invention Grant
- Patent Title: FVIII peptides and their use in tolerising haemophiliacs
- Patent Title (中): FVIII肽及其在耐药血友病患者中的应用
-
Application No.: US12746141Application Date: 2008-12-03
-
Publication No.: US08445448B2Publication Date: 2013-05-21
- Inventor: David Wraith
- Applicant: David Wraith
- Applicant Address: BE Diepenbeck
- Assignee: Apitope International NV
- Current Assignee: Apitope International NV
- Current Assignee Address: BE Diepenbeck
- Agency: Morgan, Lewis & Bockius LLP
- Priority: GB0723712.6 20071204
- International Application: PCT/GB2008/003996 WO 20081203
- International Announcement: WO2009/071886 WO 20090611
- Main IPC: A61K38/10
- IPC: A61K38/10 ; A61K38/37
Abstract:
The present invention provides a peptide comprising a core residue sequence derivable from human FVIII which peptide is capable of binding to an MHC class II molecule without further antigen processing. The present invention also relates to the use of such peptides for the prevention or suppression of inhibitor antibody formation in haemophilia A and/or acquired haemophilia.
Public/Granted literature
- US20100323966A1 FVIII Peptides and Their Use in Tolerising Haemophiliacs Public/Granted day:2010-12-23
Information query
IPC分类:
